Frontier mental health research: psychedelics & drug studies

Key findings

• Psychedelic-assisted psychotherapy can be delivered safely in clinical studies and shows promise for reducing harmful drug use, but the evidence for treating substance use disorders is still limited and not yet conclusive. ^{15051 15073 15086 15063}
• MDMA and psilocybin have stronger clinical evidence for problems like PTSD and some types of depression, while evidence for addiction is promising but smaller and earlier-stage. ^{15063 15086 15073}
• For opioid problems, new ibogaine-like compounds called oxa-iboga lowered long-term opioid use in animal tests and did not show the heart-rhythm risk seen with traditional ibogaine in lab heart-cell tests; human trials are not yet reported. ¹⁵¹¹⁵
• For methamphetamine use disorder, there are currently no approved medicines that clearly reduce cravings or long-term use; several drugs helped in animals but failed to produce lasting reductions in people. ¹⁵¹¹⁶
• 5‑MeO‑DMT is a short-acting psychedelic that produces intense experiences and brain changes that could be useful for alcohol problems, but research in humans is still early and exploratory. ¹⁵¹²²
• Good preparation and follow-up therapy (often called 'set and setting' plus integration) are widely seen as important parts of substance-assisted psychotherapy and are commonly used in clinical studies. ^{15065 15086 15051}
• Psychedelics and other psychoactive drugs can rarely cause lasting changes in perception or trigger psychosis-like problems; people with prior mental-health issues seem at higher risk, and the overall risk picture is not fully understood. ^{15097 15080}
• Traditional healers in one Ugandan district reported using many plant remedies for alcohol-related problems, but these practices have not been tested in controlled clinical trials and so cannot be judged by standard modern evidence yet. ¹⁵¹¹⁸
• Research on psychedelics has grown rapidly since the 1990s and now draws major investment and changing laws; this speeds development but raises ethical, access, and regulation questions that affect patients and practitioners. ^{15064 15087 15079 15057}
• New tools that use large language models (a kind of AI that reads and understands text) can pull out severity information from doctors' notes better than older rule-based methods, which might help clinicians plan care in the future, but these tools are not ready to replace doctors. ¹⁵¹²⁵